Phase I study of the second-generation, recombinant, human EGFR antibody necitumumab in Japanese patients with advanced solid tumors.
about
Phase I study of the second-generation, recombinant, human EGFR antibody necitumumab in Japanese patients with advanced solid tumors.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Phase I study of the second-ge ...... ts with advanced solid tumors.
@en
Phase I study of the second-ge ...... ts with advanced solid tumors.
@nl
type
label
Phase I study of the second-ge ...... ts with advanced solid tumors.
@en
Phase I study of the second-ge ...... ts with advanced solid tumors.
@nl
prefLabel
Phase I study of the second-ge ...... ts with advanced solid tumors.
@en
Phase I study of the second-ge ...... ts with advanced solid tumors.
@nl
P2093
P2860
P1476
Phase I study of the second-ge ...... ts with advanced solid tumors.
@en
P2093
Hiroshi Nokihara
Kazunori Honda
Noboru Yamamoto
Raffael Kurek
Sotaro Enatsu
Tomohide Tamura
Yasuhide Yamada
Yosuke Tamura
Yuko Tanabe
P2860
P2888
P304
P356
10.1007/S00280-016-3154-Z
P577
2016-09-15T00:00:00Z